Rethinking Alzheimer’s Care
I’m a doctor, although my approach differs from many others in the field.
My practice operates on a cash-only basis. I post prices for all services right at the entrance, so every patient—whether a high-powered executive or a factory worker—knows what to expect when they come through the door.
People from various backgrounds choose my practice, and it’s largely because there’s no interference from insurers, no hidden fees or confusing billing processes. I treat my patients without any insurance company dictating my methods.
This level of freedom is crucial. Each patient is unique and deserves a tailored plan for optimal health. Effective healthcare depends on allowing doctors and patients to collaborate on care without bureaucratic meddling. Unfortunately, this is far from the norm in American healthcare, particularly concerning Alzheimer’s disease.
By 2060, Alzheimer’s is expected to impact almost 14 million people in the U.S. The biggest hurdle to improving care isn’t scientific research; it’s policy. Government regulations and insurance restrictions hinder both early diagnosis and timely treatment, limiting physicians and patients just when swift action is most needed.
In 2025, the FDA approved a blood test that can help identify Alzheimer’s, with some studies claiming over 90% accuracy in detecting changes associated with the disease.
Detecting Alzheimer’s early opens up a valuable opportunity for patients to plan ahead and implement lifestyle changes before facing severe decline. Research suggests that up to 40% of Alzheimer’s and dementia cases might be delayed or prevented through early interventions such as exercise, good sleep, a heart-healthy diet, and social engagement.
However, early intervention hinges on effective detection.
Even when early diagnoses occur, the reimbursement policies of Medicare often disincentivize the very preventive measures patients desperately need. Counseling for prevention frequently lacks adequate compensation. Healthcare providers invest considerable time in care coordination, family education, and follow-up plans, but much of that work isn’t billable, making it difficult to sustain, no matter how dedicated the providers are.
And when lifestyle changes prove insufficient, other challenges to treatment remain.
The FDA has recently authorized two anti-amyloid therapies that can delay the progression of the disease if administered early. Achieving FDA approval takes about 10 to 15 years, requiring extensive scientific validation of safety and effectiveness. By the time a drug is approved, it has passed the highest standards in American medicine.
Despite meeting these rigorous standards, Medicare has categorized these Alzheimer’s therapies under its “Coverage with Evidence Development” policy, limiting access only to patients involved in clinical trials or data collection. This practically means that patients need to navigate additional obstacles to access treatments that are already shown to be safe and effective.
We need to adopt a more personalized strategy for Alzheimer’s care.
Most importantly, policymakers need to trust physicians to align patients with the most suitable interventions. Some people may gain more from lifestyle modifications, while others could benefit from medications, or both. Bureaucracy cannot customize care; however, doctors can.
Alzheimer’s treatment is most effective when it’s tailored. That suggests earlier diagnoses for those who might thrive through lifestyle changes and timely treatments for those who require them. The government shouldn’t micromanage these choices; instead, it should allow doctors and patients to collaborate in making them.
